Ola Dale
YOU?
Author Swipe
View article: Heightened mortality risk after a non‐fatal opioid overdose: Risk factors for mortality in the week following emergency treatment
Heightened mortality risk after a non‐fatal opioid overdose: Risk factors for mortality in the week following emergency treatment Open
Aims To measure all‐cause mortality risk after an ambulance‐attended non‐fatal opioid overdose and associations with number of days following attendance, and individual and clinical characteristics. Design A prospective observational study…
View article: Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects Open
View article: Roar Margido Stenseth
Roar Margido Stenseth Open
View article: Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone Open
View article: Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double‐dummy, randomised, controlled trial
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double‐dummy, randomised, controlled trial Open
Aims To measure and evaluate clinical response to nasal naloxone in opioid overdoses in the pre‐hospital environment. Design Randomised, controlled, double‐dummy, blinded, non‐inferiority trial, and conducted at two centres. Setting Partic…
View article: The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers Open
View article: NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use
NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use Open
Introduction Intranasal (IN) naloxone is widely used to treat opioid overdoses. The advantage of nasal administration compared with injection lies in its suitability for administration by lay people as it is needless. Approved formulations…
View article: Prehospital naloxone administration – what influences choice of dose and route of administration?
Prehospital naloxone administration – what influences choice of dose and route of administration? Open
View article: Prehospital naloxone administration – what influences choice of dose and route of administration?
Prehospital naloxone administration – what influences choice of dose and route of administration? Open
Introduction: Amidst the ongoing opioid crisis there are debates regarding the optimal route of administration and dosages of naloxone. This applies both for lay people administration and emergency medical services, and in the development …
View article: NTNU Intranasal Naloxone Trial (NINA-1) Study documents
NTNU Intranasal Naloxone Trial (NINA-1) Study documents Open
This section contains study documents forming the basis of the NINA-1 Trial. Documents will be added at Sponsors discretion, and aim to reflect the Trial Master File. Please consult the file 00readme for a key to how documents are coded in…
View article: European survey on national harmonization in clinical research
European survey on national harmonization in clinical research Open
Background Clinical trials remain key to the development of evidence‐based medical practice. However, they are becoming increasingly complex, mainly in a multinational setting. To address these challenges, the European Union (EU) adopted t…
View article: European survey on national training activities in clinical research
European survey on national training activities in clinical research Open
Background Investigator-initiated clinical studies (IITs) are crucial to generate reliable evidence that answers questions of day-to-day clinical practice. Many challenges make IITs a complex endeavour, for example, IITs often need to be m…
View article: Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine
Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine Open
View article: Pharmacokinetics of a novel, approved, 1.4‐mg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial
Pharmacokinetics of a novel, approved, 1.4‐mg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial Open
Background and aims Intranasal (i.n.) naloxone is an established treatment for opioid overdose. Anyone likely to witness an overdose should have access to the antidote. We aimed to determine whether an i.n. formulation delivering 1.4 mg na…
View article: Naloksonnesespray – biotilgjengelighet og opptaksmønster i en fase 1-studie
Naloksonnesespray – biotilgjengelighet og opptaksmønster i en fase 1-studie Open
The nasal spray resulted in a rapid systemic absorption with higher serum concentrations than intravenous naloxone 10-240 minutes after intake. The pilot study indicated that the highly concentrated nasal spray may provide a therapeutic do…
View article: Ambulance-Attended Opioid Overdoses: An Examination into Overdose Locations and the Role of a Safe Injection Facility
Ambulance-Attended Opioid Overdoses: An Examination into Overdose Locations and the Role of a Safe Injection Facility Open
Background Although the United States and numerous other countries are amidst an opioid overdose crisis, access to safe injection facilities remains limited. Methods We used prospective data from ambulance journals in Oslo, Norway, to desc…
View article: Development and course of chronic pain over 4 years in the general population: The HUNT pain study
Development and course of chronic pain over 4 years in the general population: The HUNT pain study Open
Background Epidemiological studies of chronic pain frequently report high prevalence estimates. However, there is little information about the development and natural course of chronic pain. Methods We followed a random sample of participa…
View article: Leger som hundser
Leger som hundser Open
View article: Re: Fra ketobemidon til oksykodon
Re: Fra ketobemidon til oksykodon Open
Videre skriver medisinhistoriker Aina Schiøtz at Evang spilte «en viktig rolle i det forberedende arbeidet med hensyn til kriminalisering av feltet» (7).Hvorvidt det var reell uenighet mellom Evang og Justisdepartementet, er et interessant…
View article: Ethical issues and stakeholders matter
Ethical issues and stakeholders matter Open
Commentary to: Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?
View article: Re: Fra ketobemidon til morfin eller oksykodon
Re: Fra ketobemidon til morfin eller oksykodon Open
Gi respons på artikler gjennom artiklenes kommentarfelt på tidsskriftet
View article: Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl
Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl Open
Common adverse symptoms of cancer and chemotherapy are a major health burden; chief among these is pain, with opioids including transdermal fentanyl the mainstay of treatment. Innate immune activation has been implicated generally in pain,…
View article: Renal function and symptoms/adverse effects in opioid‐treated patients with cancer
Renal function and symptoms/adverse effects in opioid‐treated patients with cancer Open
Background Renal impairment and the risk of toxicity caused by accumulation of opioids and/or active metabolites is an under‐investigated issue. This study aimed at analysing if symptoms/adverse effects in opioid‐treated patients with canc…
View article: Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids
Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids Open